19.6
Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cyto…
The mitochondrial inner membrane constitutes a series of five multi-subunit enzyme complexes responsible for transport of electrons from high-energy carriers, NADH, and FADH2, in an energetically downhill sequence, to a low-energy electron acceptor- oxygen.
The first complex-NADH-Q oxidoreductase, is the largest enzyme complex in the series, transferring electrons from NADH to coenzyme Q.
This L-shaped complex includes 45 different subunits, of which the mitochondrial genome encodes seven. Its major catalytic components are the NADH-binding site, the primary electron acceptor- FMN, and multiple iron-sulfur clusters.
The second complex is part of both the citric acid cycle and the electron transport chain. It transports electrons from succinate to FADH2 and finally to coenzyme Q via iron-sulphur clusters. This complex is therefore known as the succinate-Q reductase.
It is a nuclear-encoded tetramer with two hydrophilic subunits - A and B. Subunit-A is a flavoprotein with FAD cofactor and a succinate binding site. Subunit-B is an iron-sulfur protein with three iron-sulfur clusters. The other two subunits - C and D are hydrophobic integral-membrane proteins that contain a Q-binding site.
View the full transcript and gain access to JoVE Core videos
Q1: What is the role of Complex I in the electron transport chain?
Complex I, or NADH-Q oxidoreductase, is the largest enzyme complex in the electron transport chain, containing 45 subunits. It transfers electrons from NADH to coenzyme Q through key catalytic components including an NADH-binding site, FMN as the primary electron acceptor, and multiple iron-sulfur clusters. This initiates the energetically downhill electron transfer sequence.
Q2: How does Complex II differ from Complex I in structure and function?
Complex II, or succinate-Q reductase, is a nuclear-encoded tetramer with two hydrophilic subunits and two hydrophobic membrane proteins. Unlike Complex I, it participates in both the citric acid cycle and electron transport chain, transferring electrons from succinate through FADH2 to coenzyme Q via iron-sulfur clusters.
Q3: What are the catalytic components of Complex I?
Complex I contains three major catalytic components: an NADH-binding site where high-energy electrons enter, FMN (flavin mononucleotide) as the primary electron acceptor, and multiple iron-sulfur clusters that facilitate electron transfer. These components work together to transfer electrons from NADH to coenzyme Q in a controlled, stepwise manner.
Q4: Why is Complex I a major source of reactive oxygen species in mitochondria?
Complex I generates superoxide radicals during the large electron flow in oxidative phosphorylation. In healthy cells, ROS production is regulated at moderate levels necessary for normal cellular signaling. However, cancer cells with altered redox environments maintain elevated ROS production that triggers pro-tumorigenic pathways while exceeding normal antioxidant capacity.
Q5: How do mutations in Complex II relate to human disease?
Although rare, mutations in Complex II can lead to tumors of the carotid body, a sensory organ in the peripheral nervous system. Additionally, defects in Complex II have been linked to Huntington's disease. These mutations disrupt normal electron transport and cellular energy production, contributing to disease pathology.
Q6: What is the relationship between Complex I dysfunction and neurodegenerative disease?
In Parkinson's disease, there is a lack of function of Complex I, disrupting normal electron transport and ATP production in neurons. This mitochondrial dysfunction contributes to neurodegeneration. Complex I inhibitors like metformin can also induce programmed cell death in cancer cells by blocking respiratory functions.
Q7: How do ETC inhibitors affect cancer cells differently than normal cells?
ETC inhibitors like metformin, resveratrol, and fenretinide disrupt electron flow and trigger elevated ROS production. Cancer cells, with their altered redox environment and high antioxidant capacity, become more sensitive to ROS level alterations than normal cells. When ROS exceeds their scavenging capacity, cancer cells undergo programmed cell death.